The move includes acquisition of ONP-002, a completely synthetic neurosteroid being developed to treat mild traumatic brain injury. Credit: Rocketclips, Inc. / Shutterstock.com.

Oragenics has concluded the previously announced acquisition of assets focusing on neurological drug therapies and technologies from Odyssey Health.

The companies initially signed the agreement in October 2023.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

This strategic move includes the acquisition of a concussion product, ONP-002, and a nasal delivery device.

A completely synthetic neurosteroid, ONP-002 is being developed to treat mild traumatic brain injury and analysed as an intranasal drug to treat moderate-to-severe concussion in the acute to sub-acute stages.

Preclinical animal studies have shown that the drug can be rapidly biodistributed throughout the brain, reducing swelling, inflammation and oxidative stress. It has been shown to have a robust safety profile.

The drug has successfully concluded a Phase I trial in healthy human participants, proving safe and well-tolerated.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Oragenics is now ready for Phase II trials of ONP-002 to further assess its safety and efficacy.

The transaction also includes all of Odyssey’s rights and interests in ONP-001, a neurosteroid in development for treating Niemann pick type-C disease.

Other assets and activities of Odyssey will be maintained by the company following the neurological asset acquisition.

Oragenics CEO Kim Murphy stated: “We expect that Odyssey’s neurological pipeline will significantly expand our market opportunity and believe its technology complements our expertise in intranasal drug delivery.

“Our decision to invest in this innovative therapy is driven by our commitment to pioneering solutions that build upon our expertise in intranasal drug delivery and our dedication to improving patient outcomes.

“These new pipeline candidates hold potential to deliver innovative treatments for millions affected by mTBI and NPC and introduce Oragenics into a market that is projected to grow to $8.9bn annually by 2027.”

Odyssey’s former president and CEO Michael Redmond, had been appointed as Oragenics’ president.

He will lead the expansion of the company’s neurology product pipeline and intranasal drug delivery technologies.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
NorthWest EHealth has won three 2025 Pharmaceutical Technology Excellence Awards for Innovation, Safety and Diversity. Explore how its ConneXon platform is transforming SAE reporting and real-time safety oversight, while FARSITE delivers socio-economically inclusive recruitment to boost trial efficiency, data integrity and regulatory-grade representativeness.

Discover the Impact